Medical Devices, Diagnostics
Total Trials
1
As Lead Sponsor
0
As Collaborator
Total Enrollment
247
NCT05163080
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Phase: Phase 2
Role: Collaborator
Start: Nov 18, 2021
Completion: Aug 18, 2024
Loading map...